Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (294)	12/7/1998 7:15:00 PM
From: Ariella	Read Replies (7) \| Respond to of 1386

Ok, Ok, I think it's time for a poll/contest. My guess is that we will announce a co-partner for HU-211 on April 27, 1999 (my birthday.) Anyone else? Ariella

To: yosi s who wrote (294)	12/8/1998 8:01:00 AM
From: Ariella	Read Replies (2) \| Respond to of 1386

Am reading some of the releases available at a site mentioned by someone on the Yahoo Club thread and find a release from July 1995 announcing the marketing agreement with BOL for the Lotemax family of products. A quote: "Pharmos estimates that the worldwide opthalmic inflammation and allergy market is around $750 million." Presumably BOL provided PARS with this figure and it included all three eye drugs. If it were accurate and we got 15% market share, that would make our final cut $22.5 million-$30 million/year once the product roll-out is completed. BOL's cut would be $80 million- $106 million, something definitely worth moving a little faster for! Hope they still have their calculators out. Ariella